ALTEOGEN Inc Total Liabilities
ALTEOGEN Inc total liabilities. Based on the latest financial reports, ALTEOGEN Inc (196170) has total liabilities worth ₩192.66 Billion KRW (≈ $130.57 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of ALTEOGEN Inc to measure how many days the company can operate on defensive assets alone.
Total Liabilities of ALTEOGEN Inc (2014–2025)
Total liabilities of ALTEOGEN Inc from 2014 to 2025. This chart illustrates how ALTEOGEN Inc's total liabilities have evolved over time, based on quarterly financial data. Check 196170 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
ALTEOGEN Inc Competitors by Total Liabilities
The table below lists competitors of ALTEOGEN Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Repligen Corporation
NASDAQ:RGEN
|
USA | $838.15 Million |
|
AVIC Jonhon Optronic Technology Co Ltd
SHE:002179
|
China | CN¥16.19 Billion |
|
Advanced Drainage Systems Inc
NYSE:WMS
|
USA | $2.55 Billion |
|
YARA INTL ASA ADR NK170
F:IU20
|
Germany | €8.69 Billion |
|
Walgreens Boots Alliance Inc
NASDAQ:WBA
|
USA | $62.09 Billion |
|
Industrial Bank Of Korea
KO:024110
|
Korea | ₩463.84 Trillion |
|
Stifel Financial Corporation
NYSE:SF
|
USA | $38.89 Billion |
|
Dino Polska SA
WAR:DNP
|
Poland | zł6.34 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down ALTEOGEN Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of ALTEOGEN Inc.
Liquidity & Leverage Metrics
ALTEOGEN Inc Total Liabilities Ratios Explained
ALTEOGEN Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ALTEOGEN Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ALTEOGEN Inc (2014–2025)
The table below shows the annual total liabilities of ALTEOGEN Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩244.30 Billion ≈ $165.56 Million |
+81.07% |
| 2024-12-31 | ₩134.92 Billion ≈ $91.43 Million |
+24.63% |
| 2023-12-31 | ₩108.26 Billion ≈ $73.37 Million |
+11.92% |
| 2022-12-31 | ₩96.73 Billion ≈ $65.55 Million |
-21.74% |
| 2021-12-31 | ₩123.61 Billion ≈ $83.77 Million |
+340.77% |
| 2020-12-31 | ₩28.04 Billion ≈ $19.00 Million |
+75.31% |
| 2019-12-31 | ₩16.00 Billion ≈ $10.84 Million |
+236.41% |
| 2018-12-31 | ₩4.76 Billion ≈ $3.22 Million |
+50.08% |
| 2017-12-31 | ₩3.17 Billion ≈ $2.15 Million |
+16.44% |
| 2016-12-31 | ₩2.72 Billion ≈ $1.84 Million |
+226.01% |
| 2015-12-31 | ₩834.62 Million ≈ $565.61K |
-60.88% |
| 2014-12-31 | ₩2.13 Billion ≈ $1.45 Million |
-- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more